Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
NCT04243473 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2026-03-03
Summary
The primary goal of this tissue collection protocol is to establish a framework for the acquisition and banking of biospecimen collected from men undergoing brachytherapy. Biopsies of the prostate is an invasive procedure; however, in this tissue collection protocol, biopsies are acquired intraoperatively while patients are prepped for brachytherapy seed placement, thus minimizing the inconvenience of the biopsy procedure for patients. The utility of these biopsies will provide a valuable resource for molecular assessments.
Conditions
Sponsors & Collaborators
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
lead OTHER
Principal Investigators
-
Daniel Song, MD · Johns Hopkins SKCCC
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-31
- Primary Completion
- 2026-01-31
- Completion
- 2026-01-19
Countries
- United States
Study Locations
More Related Trials
-
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
NCT02225925 ·Status: COMPLETED ·Phase: NA
-
Oral Colchicine in Men With Castrate Resistant Prostate Cancer
NCT01481233 ·Status: WITHDRAWN ·Phase: PHASE2
-
Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer
NCT01983709 ·Status: TERMINATED ·Phase: PHASE1
-
Pre-Prostatectomy Lovastatin on Prostate Cancer
NCT01478828 ·Status: TERMINATED ·Phase: NA
-
CCI-779 in Treating Patients With Prostate Cancer
NCT00012142 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
NCT06094842 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer
NCT01084759 ·Status: COMPLETED ·Phase: NA
-
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
NCT02346526 ·Status: COMPLETED ·Phase: PHASE2
-
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
NCT01335204 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Definitive Therapy to Treat Prostate Cancer
NCT02716974 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
NCT03741712 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
NCT02494713 ·Status: TERMINATED ·Phase: PHASE2
-
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
NCT02489357 ·Status: COMPLETED ·Phase: NA
-
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT05241613 ·Status: TERMINATED ·Phase: PHASE1
-
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
NCT00147212 ·Status: COMPLETED ·Phase: PHASE2
-
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
NCT03545165 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Surgery in Treating Patients With Prostate Cancer
NCT00002938 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04886986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Organoids From Metastases of Prostate Cancer
NCT03952793 ·Status: TERMINATED ·Phase: NA
-
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
NCT00003534 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients
NCT03465345 ·Status: WITHDRAWN ·Phase: PHASE1
-
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
NCT03896984 ·Status: COMPLETED
-
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
NCT04279561 ·Status: TERMINATED ·Phase: PHASE1
-
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
NCT04249947 ·Status: TERMINATED ·Phase: PHASE1
-
Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
NCT02370355 ·Status: TERMINATED